Last reviewed · How we verify
NCT03338712
Micro-RNA Expression Profiles in Localised Prostate Cancer
trial in Prostate Cancer. Withdrawn.
1 April 2016
Quick facts
| Lead sponsor | Wuerzburg University Hospital |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 February 2010 |
| Primary completion | 1 April 2016 |
| Estimated completion | 1 April 2016 |
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Radical Prostatectomy — all drugs for Radical Prostatectomy →
Sponsor
Wuerzburg University Hospital
Who can join
Adults 35 to 80, male only, with Prostate Cancer or Radical Prostatectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
Verify or expand the search:
- PubMed search for NCT03338712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Wuerzburg University Hospital trials
Trials by the same sponsor.
- NCT07084480 — Giant Cell Arteritis - Ways to Precision Medicine · recruiting
- NCT07040189 — Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders · NA · not yet recruiting
- NCT06550908 — Training Physicians to Differentiate the Paris Classification Using Artificial Colon Polyp Images · NA · recruiting
- NCT07108569 — Ability of Physicians to Distinguish Real From Artificial Colon Polyp Images · NA · completed
- NCT06553326 — EndoStyle: Artificial Intelligence Image Transformation Tool for Colonoscopy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03338712 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuerzburg University Hospital
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03338712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing